Who are Ciclopirox 8%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ciclopirox NL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ciclopirox-8.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ciclopirox 8% — Competitive Intelligence Brief

Ciclopirox 8% (Ciclopirox 8%) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antifungal agent. Area: Dermatology/Infectious Disease.

marketed Topical antifungal agent Fungal cytochrome P450 enzymes and polyvalent cation-dependent metalloenzymes Dermatology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ciclopirox 8% (Ciclopirox 8%) — MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA. Ciclopirox is a broad-spectrum antifungal agent that inhibits fungal enzyme systems by chelating polyvalent cations, disrupting cellular respiration and biosynthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ciclopirox 8% TARGET	Ciclopirox 8%	MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA	marketed	Topical antifungal agent	Fungal cytochrome P450 enzymes and polyvalent cation-dependent metalloenzymes
Ciclopirox NL	Ciclopirox NL	Galderma R&D	marketed	Topical antifungal agent	Fungal cytochrome P450 enzymes (via metal ion chelation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antifungal agent class)

Galderma R&D · 1 drug in this class
MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ciclopirox 8% — Competitive Intelligence Brief. https://druglandscape.com/ci/ciclopirox-8. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab